Navigation Links
MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium
Date:12/4/2012

MONTCLAIR, N.J., Dec. 4, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that John S. Condeelis, Ph.D., Chairman of MetaStat's Scientific Advisory Board, and Joan Jones, M.D., a member of MetaStat's Clinical Advisory Board, will be presenting data on the Company's licensed metastatic breast cancer markers at the CTRC-AACR 2012 San Antonio Breast Cancer Symposium on December 4-8, 2012, in San Antonio, Texas.

About MetaStat, Inc.

MetaStat was formed to help cancer patients benefit from recent discoveries in how cancer spreads through the bloodstream to other organs in the body in a process called metastasis. We believe our MetaSite Breast™ and MenaCalc™ diagnostic product lines will accurately predict the probability of cancer metastasizing. They are intended to allow clinicians to better "customize" cancer treatment decisions by positively identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and/or radiation therapies. Furthermore, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid epithelial cancers, including breast, prostate, lung and colorectal, which account for over 50% of all new cancer cases in the U.S. each year. As such, we believe our diagnostic products represent a significant breakthrough for cancer patients and their doctors because 90% of all solid tumor cancer deaths are due from metastasis.

Additionally, we believe our MenaBloc™ technology provides us with targets of intervention in key pathways for the development of targeted therapeutics that may preemptively reduce or eliminate metastasis in these tumor types.

Our technology platform(s) and corresponding products are the result of over 15 years of collaboration involving four scientific/academic institutions. We believe we are unique and differentiated in the marketplace. Our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo, which enabled us to specifically isolate and thus characterize the behavior, genetics and mechanics of these highly metastatic cells.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Contact: 
For More Information, 
Warren C. Lau 
President & CEO 
MetaStat, Inc. 
(973) 744-7618 
warren@metastat.com


'/>"/>
SOURCE MetaStat, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. MetaStat, Inc. Executes Two New Licenses
4. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
7. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
8. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
9. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
10. MetaStat Announces Stock Trading on OTC Bulletin Board
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... In his latest video, ... traits in humans. Using presidential candidate Donald Trump as an example, Kalsi describes ... “AstroNumerology is not about adding numbers up,” says Kalsi. “It is about looking ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Phynd Technologies, Inc. ... GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, NJ. ... three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta ... of New Jersey in the class of 1986, where he graduated in the top ... his current location in Livingston since 1989. He has been a member in good ...
(Date:5/31/2016)... ... ... Super Powder, a supplement produced by Prox Formulas for providing protein ... to transform the nutritional supplement industry by providing a safe, natural approach to enhanced ... (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit A, B1, ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts on June ... summer camp offers families and children a fun and unique experience with an ...
Breaking Medicine News(10 mins):